Skip to content

Seeking Objectivity in Allocation of Advanced Heart Failure (SOCIAL HF) Therapies Trial

Seeking Objectivity in Allocation of Advanced Heart Failure (SOCIAL HF) Therapies Trial

Status
Enrolling by invitation
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05390411
Acronym
SOCIAL HF
Enrollment
1463
Registered
2022-05-25
Start date
2023-03-06
Completion date
2027-09-30
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Decision Making, Heart Transplant, Implementation Science

Keywords

Healthcare Disparities

Brief summary

The primary goal of this study is to assess real-world effectiveness and implementation of an evidence-based multi-component strategy to reduce disparities in the allocation rate of advanced heart failure therapies, heart transplants and ventricular assist devices. This study proposes to implement evidence-based strategies that reduce unequal and unethical decision-making towards patients, replace subjective evaluations with objective criteria, and improve group dynamics in a randomized cluster trial. Our rigorously designed trial will inform national guidelines for advanced heart failure therapy allocation, and data are likely to be generalizable to other organ replacement treatments and advanced chronic disease decision-making processes across populations.

Detailed description

Standardized protocols can reduce the impact of unfair and unequal treatment but are underused. Since the Institute of Medicine's report, "Unequal Treatment", multiple studies have confirmed that standardization of decision-making processes reduces unequal treatment, but unequal and unethical perceptions in decision-making in the allocation of advanced therapies has not been addressed. Using an evidence-based framework for behavior change \[Capability, Opportunity, and Motivation for Behavior Change/Behavior Change Wheel (COM-B/BCW)\], we developed a standardized protocol strategy, Seeking Objectivity in Allocation of Advanced Heart Failure (SOCIAL HF), that addresses the most significant barriers to equality in advanced therapies: 1) unequal and unethical perceptions that influence decision-making, 2) subjectivity in evaluation of social support and adherence, and 3) poor group dynamics. Thus, SOCIAL HF includes: 1) evidence-based training to reduce disparities tailored for HF, 2) restriction to objective evaluations of social support and adherence, and 3) environmental restructuring and modeling of meeting settings to include anonymous electronic voting and more fair-minded seating arrangement. In complex decision-making that includes individuals and groups, our standardized protocol strategy, SOCIAL HF, has the greatest likelihood of reducing health disparities in advanced HF. Our goal is to assess real-world effectiveness (Aim 1) and implementation (Aim 2) of SOCIAL HF for allocation of advanced HF therapies, heart transplant and ventricular assist device implantation. As a type 2 effectiveness-implementation hybrid study, we will use a cluster randomized design to test the effectiveness of SOCIAL HF strategy. We will evaluate implementation of SOCIAL HF across study sites using mixed-methods to learn optimal implementation strategies to reduce disparities in accessing life-saving therapies. We will use normalization process theory to evaluate how SOCIAL HF affects processes and outcomes important to advanced HF centers (e.g. fidelity/variation). We will use RE-AIM framework (reach, effectiveness, adoption, implementation, and maintenance) to evaluate factors that promote reach and adoption and resources needed for implementation. We have the relationships, infrastructure, and expertise to execute this project; our multidisciplinary team includes experts in HF, evidence-based training in reducing unequal and unethical perceptions in decision-making, clinical trials, mixed-methods, and implementation science.

Interventions

BEHAVIORALSOCIAL HF

participate in SOCIAL HF training

Sponsors

Indiana University
Lead SponsorOTHER
National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Intervention model description

Pragmatic randomized controlled cluster trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Active United Network for Organ Sharing heart transplant and ventricular assist device center 2. Centers that routinely evaluate at least 50 minoritized racial/ethnic patients and 50 women for advanced heart failure therapies (heart transplant and ventricular assist device) over 2 years 3. Advanced therapy professionals from participating centers (i.e., coordinators, physicians, pharmacists, nurses, social workers) 4. Participants for the interview portion will be a subset of otherwise eligible advanced therapy professionals who are included on selection meeting attendance sheets at an included center

Exclusion criteria

1. Centers unable to fully participate in the training and evaluation measures 2. If the center ceases to be an active heart failure/transplant center

Design outcomes

Primary

MeasureTime frameDescription
Proportion of evaluated minoritized racial/ethnic patients and women patients receiving advanced therapies.Up to 2 years
Change in SOCIAL HF fidelity from time of training completion (month 2) to time study target has been reached (up to 2 years) and 6 months after reaching study target (up to 2.5 years)Month 2, up to 2 years, and up to 2.5 yearsEvaluated as barriers, facilitators, and variability in adoption, reach, implementation and maintenance through structured interviews. Study target is defined as time 50 patients of color and 50 women have been evaluated for advanced heart failure therapies per center.

Secondary

MeasureTime frameDescription
Change from baseline knowledge, attitudes, and self-reported behavior change among clinicians at 2 months and time at which study target has been reached (up to 2 years)Baseline, 2 months, and up to 2 yearsMultiple survey responses by participants will indicate knowledge, attitudes, and self-reported behavior changes over time. Study target is defined as time 50 patients of color and 50 women have been evaluated for advanced heart failure therapies.
Discussion themes during allocation meetings across patient race/ethnicity and sexBaseline, 2 months, and up to 2 yearsTranscriptions of meetings will be qualitatively evaluated over time.
Change from baseline sum group function scores at 2 months and time at which study target has been reached (up to 2 years)Baseline, 2 months, and up to 2 yearsThe de Groot Critically Reflective Diagnoses protocol objectively measures categories associated with group function including challenging groupthink, critical opinion sharing, research utilization, openness to mistakes, asking and giving feedback, and experimentation. Each category is scaled from 1-4 (high-low), 1 = demonstrating interaction and reflection, 2 = reflective on an individual basis, 3 = non-reflective and non-interactive, and 4 = restricted. Study target is defined as time 50 patients of color and 50 women have been evaluated for advanced heart failure therapies per center.
Adoption of SOCIAL HF2 monthsProportion of eligible advanced therapy professionals who participate in training
Reach of SOCIAL HFFrom 2 months up to 2 yearsProportion of patients evaluated using any parts of SOCIAL HF
Implementation of SOCIAL HFFrom 2 months up to 2 yearsProportion of patients evaluated using all parts of SOCIAL HF

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORKhadijah Breathett, MD, MS

Indiana University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 4, 2026